Revelation Biosciences, Inc. (REVBW) stock
REVBWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as REVB
$0.01+0.00 (0.00%)
Close on Oct 30, 2026Market cap $16.05MP/E –Yield –
Revelation Biosciences free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Revelation Biosciences's free cash flow for the twelve months ending Dec 31, 2024 was -$18.34M. For fiscal 2024 it was -$18.34M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$18.34M | – |
| FY2021 | Dec 31, 2021 | -$11.22M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.60M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.29M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.73M | – |
| Q3 FY2024 | Sep 30, 2024 | -$9.27M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.48M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.86M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.72M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.99M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.58M | – |
| Q4 FY2021 | Dec 31, 2021 | -$2.86M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.23M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.64M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.48M | – |